13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001587114
Total reported value
$2.1B
$2.1B
57 檔
57.8%
In Q4 2024, EcoR1 Capital, LLC's U.S. equity holdings reached a combined market value of $2.1B, distributed across 57 disclosed stock positions.
In Q4 2024, EcoR1 Capital, LLC adopted a defensive or profit-taking posture, trimming 9 positions and completely liquidating 16 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including APLSUSD, ZYME, CRNX) accounted for 57.8% of total reported equity market value during Q4 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 14.35% | — | — | |
| 2 | ZYME | Zymeworks Inc | Stock-Other | 8.32% | +4.78% | +11.84% | |
| 3 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 8.29% | -6.61% | EXIT | |
| 4 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 7.95% | -13.69% | EXIT | |
| 5 | PRTA | Prothena Corporation plc | Stock-Other | 6.07% | — | — | |
| 6 | XNCR | Xencor Inc | Stock-Other | 5.34% | -1.12% | EXIT | |
| 7 | PFE | Pfizer Inc | Stock-Healthcare | 5.01% | — | — | |
| 8 | ARVN | Arvinas Inc | Stock-Other | 4.87% | — | — | |
| 9 | ANAB | Anaptysbio Inc | Stock-Other | 3.94% | +7.31% | +1.01% | |
| 10 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 3.54% | — | — | |
| 11 | JANX | Janux Therapeutics Inc | Stock-Other | 2.98% | — | — | |
| 12 | QURE | uniQure N.V. | Stock-Other | 2.53% | — | — | |
| 13 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 2.13% | — | — | |
| 14 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 2.07% | +0.88% | — | |
| 15 | IMNM | Immunome Inc | Stock-Other | 1.56% | — | — | |
| 16 | TECX | Tectonic Therapeutic Inc | Stock-Other | 1.48% | — | — | |
| 17 | TNGX | Tango Therapeutics Inc | Stock-Other | 1.24% | — | -20.25% | |
| 18 | ✓ | Third Harmonic Bio Inc | Stock-Other | 1.24% | — | — | |
| 19 | KURA | Kura Oncology Inc | Stock-Other | 1.17% | — | -38.74% | |
| 20 | NGNE | Neurogene Inc | Stock-Other | 1.10% | +0.85% | — | |
| 21 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 1.04% | -0.08% | — | |
| 22 | ETON | Eton Pharmaceuticals Inc | Stock-Other | 1.00% | +1.55% | +149.47% | |
| 23 | MBX | Mbx Biosciences Inc | Stock-Other | 0.88% | +0.06% | +7.10% | |
| 24 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 0.87% | — | — | |
| 25 | VYGR | Voyager Therapeutics Inc | Stock-Other | 0.84% | — | — | |
| 26 | NMRA | Neumora Therapeutics Inc | Stock-Other | 0.83% | — | — | |
| 27 | CRGX | Cargo Therapeutics Inc | Stock-Other | 0.80% | — | — | |
| 28 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 0.68% | — | — | |
| 29 | DNA | Ginkgo Bioworks Holdings Inc | Stock-Other | 0.65% | — | — | |
| 30 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 0.61% | — | -26.40% | |
| 31 | ✓ | Mersana Therapeutics Inc | Stock-Other | 0.61% | — | -41.50% | |
| 32 | TCRX | Tscan Therapeutics Inc | Stock-Other | 0.57% | — | — | |
| 33 | ADAPY | Adaptimmune Therapeutics-adr | Stock-Other | 0.56% | — | — | |
| 34 | KYMR | Kymera Therapeutics Inc | Stock-Other | 0.53% | — | — | |
| 35 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.49% | — | — | |
| 36 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.48% | — | — | |
| 37 | AVIR | Atea Pharmaceuticals Inc | Stock-Other | 0.42% | — | -38.59% | |
| 38 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 0.41% | — | — | |
| 39 | REPL | Replimune Group Inc | Stock-Other | 0.39% | -0.32% | EXIT | |
| 40 | ALGS | Aligos Therapeutics Inc | Stock-Other | 0.38% | — | — | |
| 41 | ATRA | Atara Biotherapeutics Inc | Stock-Other | 0.27% | +0.85% | +13.48% | |
| 42 | ✓ | Verve Therapeutics Inc | Stock-Other | 0.27% | — | — | |
| 43 | FATE | Fate Therapeutics Inc | Stock-Other | 0.19% | — | — | |
| 44 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 0.16% | +0.31% | — | |
| 45 | ✓ | Stock-Other | 0.15% | — | -96.38% | ||
| 46 | KROS | Keros Therapeutics Inc | Stock-Other | 0.11% | — | — | |
| 47 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.10% | -0.17% | -74.34% | |
| 48 | DSGN | Design Therapeutics Inc | Stock-Other | 0.10% | — | +692.59% | |
| 49 | NUVB-WS | Nuvation Bio Inc -cw27 | Stock-Other | 0.10% | — | — | |
| 50 | GBIOGBX | Generation Bio Co | Stock-Other | 0.08% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PFE | Pfizer Inc | +5% | NEW | New buy |
| 2 | SRPT | Sarepta Therapeutics Inc | +3.5% | NEW | New buy |
| 3 | APLSUSD | Apellis Pharmaceuticals Inc | +2.6% | — | Unchanged |
| 4 | ZYME | Zymeworks Inc | +2.6% | +11.84% | Add |
| 5 | QURE | uniQure N.V. | +2.5% | NEW | New buy |
| 6 | SWTXUSD | Springworks Therapeutics Inc | +2.1% | NEW | New buy |
| 7 | XNCR | Xencor Inc | +1.7% | +15.28% | Add |
| 8 | JAZZ | Jazz Pharmaceuticals plc | +1.4% | — | Unchanged |
| 9 | ETON | Eton Pharmaceuticals Inc | +0.8% | +149.47% | Add |
| 10 | CRNX | Crinetics Pharmaceuticals In | +0.8% | — | Unchanged |
| 11 | JANX | Janux Therapeutics Inc | +0.7% | — | Unchanged |
| 12 | MLTX | Moonlake Immunotherapeutics | +0.7% | NEW | New buy |
| 13 | DNA | Ginkgo Bioworks Holdings Inc | +0.7% | NEW | New buy |
| 14 | TECX | Tectonic Therapeutic Inc | +0.6% | — | Unchanged |
| 15 | KYMR | Kymera Therapeutics Inc | +0.5% | NEW | New buy |
| 16 | MDGL | Madrigal Pharmaceuticals Inc | +0.3% | — | Unchanged |
| 17 | ALGS | Aligos Therapeutics Inc | +0.3% | — | Unchanged |
| 18 | FATE | Fate Therapeutics Inc | +0.2% | NEW | New buy |
| 19 | ATRA | Atara Biotherapeutics Inc | +0.1% | +13.48% | Add |
| 20 | DSGN | Design Therapeutics Inc | +0.1% | +692.59% | Add |
| 21 | REPL | Replimune Group Inc | +0.1% | — | Unchanged |
| 22 | ✓ | Verve Therapeutics Inc | +0.1% | — | Unchanged |
| 23 | VYGR | Voyager Therapeutics Inc | +0.1% | — | Unchanged |
| 24 | UPB | Upstream Bio Inc | 0% | NEW | New buy |
| 25 | NUVB-WS | Nuvation Bio Inc -cw27 | 0% | — | Unchanged |
| 26 | LKFT | Lakefront Biotherapeutic-adr | 0% | — | Unchanged |
| 27 | SRZNW | Surrozen Inc-cw25 | 0% | — | Unchanged |
| 28 | GLUE | Monte Rosa Therapeutics Inc | 0% | NEW | New buy |
| 29 | DAWNGBX | Day One Biopharmaceuticals I | — | — | Unchanged |
| 30 | ARTV | Artiva Biotherapeutics Inc | — | — | Unchanged |
| 31 | ALLKGUSD | Allakos Inc | — | EXIT | Sold out |
| 32 | PRME | Prime Medicine Inc | 0% | — | Unchanged |
| 33 | MGNX | Macrogenics Inc | 0% | EXIT | Sold out |
| 34 | ✓ | 0% | EXIT | Sold out | |
| 35 | ✓ | -0.1% | -31.98% | Trim | |
| 36 | KYTX | Kyverna Therapeutics Inc | -0.1% | EXIT | Sold out |
| 37 | GBIOGBX | Generation Bio Co | -0.1% | — | Unchanged |
| 38 | WHWK | Whitehawk Therapeutics Inc | -0.1% | -81.29% | Trim |
| 39 | NMRA | Neumora Therapeutics Inc | -0.1% | — | Unchanged |
| 40 | ✓ | Proqr Therapeutics N.v. | -0.1% | EXIT | Sold out |
| 41 | CRGX | Cargo Therapeutics Inc | -0.1% | — | Unchanged |
| 42 | BBIO | Bridgebio Pharma Inc | -0.2% | EXIT | Sold out |
| 43 | CRSP | CRISPR Therapeutics AG | -0.2% | — | Unchanged |
| 44 | ORIC | Oric Pharmaceuticals Inc | -0.2% | — | Unchanged |
| 45 | ✓ | -0.2% | -96.38% | Trim | |
| 46 | MBX | Mbx Biosciences Inc | -0.2% | +7.10% | Add |
| 47 | DYN | Dyne Therapeutics Inc | -0.2% | — | Unchanged |
| 48 | AVIR | Atea Pharmaceuticals Inc | -0.2% | -38.59% | Trim |
| 49 | BCYC | Bicycle Therapeutics Plc-adr | -0.2% | — | Unchanged |
| 50 | ✓ | Third Harmonic Bio Inc | -0.2% | — | Unchanged |
According to official SEC Form 13F filings, EcoR1 Capital, LLC reported a total U.S. public equity portfolio value of $2.1B across 57 disclosed positions in Q4 2024.
During Q4 2024, EcoR1 Capital, LLC's top holdings by market value included APLSUSD (14.3%)、ZYME (8.3%)、CRNX (8.3%). The largest single position, APLSUSD, represented 14.3% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
PFE
市值: $132.7M
Top Position Liquidated / Trimmed
260
前期市值: $51.5M
In Q4 2024, EcoR1 Capital, LLC made 42 total portfolio adjustments, initiating 10 new buys, adding to 7 positions, trimming 9 holdings, and fully liquidating 16 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.